Significant cash drain in the Q1
23/05/24 -"CureVac has released its Q1 figures, which unexpectedly show a significant cash drain due to raw material commitments. However, one positive note is the management’s confirmation that the cash ..."
Pages
51
Language
English
Published on
23/05/24
You may also be interested by these reports :
14/06/24
When we last teased Lundbeck’s (BUY; Denmark) story in May 2023, the share price had fiercely recovered (>45%) from the October 2022 lows, and the ...
12/06/24
Portfolio news flow likely to support NAV growth in the medium term
12/06/24
Siegfried to acquire early-phase CDMO in the U.S., outlook reiterated
04/06/24
GSK lost c.9% (i.e. £6.2bn or $7.9bn) of its market cap yesterday after the Delaware (US) Court, in Zantac litigations, allowed the plaintiffs’ ...